Cryptic susceptibility to penicillin/β-lactamase inhibitor combinations in emerging multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages

Nat Commun. 2023 Oct 14;14(1):6479. doi: 10.1038/s41467-023-42245-y.

Abstract

Global spread of multidrug-resistant, hospital-adapted Staphylococcus epidermidis lineages underscores the need for new therapeutic strategies. Here we show that many S. epidermidis isolates belonging to these lineages display cryptic susceptibility to penicillin/β-lactamase inhibitor combinations under in vitro conditions, despite carrying the methicillin resistance gene mecA. Using a mouse thigh model of S. epidermidis infection, we demonstrate that single-dose treatment with amoxicillin/clavulanic acid significantly reduces methicillin-resistant S. epidermidis loads without leading to detectable resistance development. On the other hand, we also show that methicillin-resistant S. epidermidis is capable of developing increased resistance to amoxicillin/clavulanic acid during long-term in vitro exposure to these drugs. These findings suggest that penicillin/β-lactamase inhibitor combinations could be a promising therapeutic candidate for treatment of a high proportion of methicillin-resistant S. epidermidis infections, although the in vivo risk of resistance development needs to be further addressed before they can be incorporated into clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amoxicillin / pharmacology
  • Amoxicillin / therapeutic use
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clavulanic Acid / pharmacology
  • Clavulanic Acid / therapeutic use
  • Humans
  • Microbial Sensitivity Tests
  • Penicillins* / pharmacology
  • Penicillins* / therapeutic use
  • Staphylococcal Infections* / drug therapy
  • Staphylococcus epidermidis
  • beta-Lactamase Inhibitors / pharmacology

Substances

  • Penicillins
  • beta-Lactamase Inhibitors
  • Clavulanic Acid
  • Amoxicillin
  • Anti-Bacterial Agents